Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.37 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 2/20 | 0.37 |
| ▸ | FGF1 | P05230 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264356 | 0.94 | LGALS8 (0.43) | L3MBTL1MAPTPYGBLGALS8LGALS1 | |
| SCHEMBL17370176 | 0.85 | G6PD (0.32) | OGA | |
| SCHEMBL15958442 | 0.85 | AMY2A (0.39) | L3MBTL1MAPTPYGBLGALS8OGA | |
| SCHEMBL19788485 | 0.84 | OGA (0.35) | OGAFGF1 | |
| SCHEMBL21141258 | 0.80 | PYGB (0.44) | L3MBTL1PYGBLGALS8LGALS1LGALS3 | |
| SCHEMBL23591372 | 0.80 | L3MBTL1 (0.46) | L3MBTL1MAPTPYGBLGALS8LGALS1 | |
| SCHEMBL25140767 | 0.80 | L3MBTL1 (0.46) | L3MBTL1MAPTPYGBLGALS8LGALS1 | |
| SCHEMBL22011079 | 0.80 | L3MBTL1 (0.46) | L3MBTL1MAPTPYGBLGALS8LGALS1 | |
| SCHEMBL19430676 | 0.80 | L3MBTL1 (0.46) | L3MBTL1MAPTPYGBLGALS8LGALS1 | |
| SCHEMBL10147764 | 0.80 | L3MBTL1 (0.46) | L3MBTL1MAPTPYGBLGALS8LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20220098585-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | L3MBTL1 490/4885MAPT 4649/4885PYGB 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.